New Alzheimer's drug deemed too costly for UK's state-run health service
Eisai-Biogen drug first treatment to slow Alzheimer's course
UK draft guidance on cost a blow after slow take-up in U.S.
Adds Biogen shares in paragraph 10 and analyst comment in paragraph 19
By Maggie Fick
Aug 22 (Reuters) -Alzheimer's patients in Britain's state-run health service are unlikely to get access to Eisai 4523.T and Biogen's BIIB.O new Leqembi drug, after it was approved on Thursday by the country's regulator but deemed too expensive for wide use.
The Medicines and Healthcare products Regulatory Agency (MHRA) said the drug, also known as lecanemab, is the first treatment for Alzheimer's licensed for use in the country that shows some evidence of slowing the progression of the disease.
But in draft guidance published simultaneously, the National Institute for Health and Care Excellence (NICE), said the medicine's high cost and need for intensive monitoring for side effects "means it cannot be considered good value for the taxpayer".
NICE also cited a lack of evidence on the long-term effects of taking the treatment, noting that the clinical trial only reported outcomes when people had been taking lecanemab for 18 months.
The UK cost effectiveness body's findings mark the latest blow faced by the drugmakers amid slow take-up of the drug in the U.S. due to the cost and concerns over side effects and efficacy.
It also highlights the complexities of a new class of drugs that benefit early-stage Alzheimer's patients but carry the risk of rare and serious side effects.
NICE's guidance on the drug is open for public consultation until Sept. 20, and a final recommendation will follow its evaluation of the responses.
NICE also said that around 70,000 adults in England would have been eligible for treatment with drug.
Eisai and Biogen said they are working with NICE, the Scottish Medicines Consortium and the National Health Service to make Leqembi available “as soon as possible.”
Shares of Biogen were down 1.3% at $203.52 in early trading.
Professor Paul Morgan, Interim Director of the UK Dementia Research Institute Cardiff, at Cardiff University in Wales, said that while NICE's decision would disappoint people with high hopes for the new therapy, the body's "wait and see" approach was understandable given what he called "unanswered questions" about the long-term impact and side effects.
Another dementia expert, Professor Vanessa Raymont, an associate professor in the psychiatry department at the University of Oxford, said that while new treatments for Alzheimer's are critical, blood tests to diagnose the memory-robbing disease are equally as important.
Experts and company executives told Reuters last year that while several such tests are in development, it will be another couple of years before they become an everyday tool.
SIDE EFFECTS
Lecanemab slowed progress of Alzheimer's disease by 27% compared with a placebo, in a large trial whose outcomes were reported by the companies in 2022.
The therapy has been approved in the United States, China, Hong Kong, Israel, Japan, South Korea and the UAE.
But last month the European Union's drugs regulator rejected the drug, saying the risk of serious brain swelling did not outweigh its small impact on slowing cognitive decline.
The companies said then that they would seek re-examination of the recommendation, but did not disclose what information they would provide the regulator.
An approval in Britain is a significant step in realizing the estimated $1.6 billion in revenue from Europe for Leqembi, "a critical approval that is needed to further accelerate sales for the drug," BMO Capital Markets analyst Evan Seigerman said.
The infusion, given twice a month, removes sticky clumps of protein amyloid beta from the brain, believed to be a hallmark of Alzheimer's disease.
It has been associated with serious side effects for some patients, including brain swelling and bleeding or microhemorrhages.
Leqembi treatment is priced at $26,500 a year in the U.S. In Britain, the NICE draft guidance stated that the price is confidential until published by the UK's Department for Health and Social Care.
For now, aside from Leqembi, there is only one other Alzheimer's drug on the market designed to slow the course of the disease: Eli Lilly's LLY.N drug donanemab, approved by the U.S. Food and Drug Administration last month.
Reporting by Maggie Fick in London and Prerna Bedi in Bengaluru, additional reporting by Sneha S K; Editing by Sherry Jacob-Phillips and Jane Merriman
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
